Stanley Ngan

Stanley serves as a Director of Regulatory Affairs at 4D Molecular Therapeutics (4DMT), a clinical-stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market diseases. With over 16 years of experience in the biopharma industry, Stanley possesses extensive regulatory knowledge across drug product life cycles in the United States and international markets. At 4DMT, he focuses on the development of a combination product with an inhaled genetic medicine for the treatment of cystic fibrosis lung disease. He is the main point of contact at 4DMT for communications with the FDA and has extensive experience in interacting with global regulatory agencies. Stanley received a B.A. in Molecular and Cell Biology from University of California, Berkeley.